)
Visual
earnings real time
Structure Therapeutics (GPCR) investor relations material
Structure Therapeutics Study Update summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Study Update summary8 Dec, 2025
Study design and objectives
Phase 2b ACCESS and supplementary studies evaluated efficacy, safety, and tolerability of Eleniglipron/Aleniglipron in adults with obesity or overweight plus comorbidities, using doses up to 240 mg over 36–44 weeks, with alternative titration schemes and exploratory studies at higher doses.
Participants were randomized to active drug (45, 90, 120 mg) or placebo, with a 5 mg starting dose and four-week titration steps; key endpoints included percent body weight reduction and secondary metabolic outcomes.
Over 500 participants were treated across all studies, including open-label extension and body composition studies using a lower 2.5 mg starting dose to improve tolerability.
Studies addressed weight loss durability, higher dosing, and improved tolerability with lower starting dose.
Phase 3 program is planned to start mid-2026, with an FDA meeting in early 2026 to finalize design.
Efficacy and weight loss outcomes
At 36 weeks, placebo-adjusted mean weight loss was 8.2% (45 mg), 9.8% (90 mg), and 11.3% (120 mg), with up to 15.3% at 240 mg in exploratory studies; all doses achieved statistical significance on primary and key secondary endpoints.
No evidence of weight loss plateau through 44 weeks; weight loss continued in open-label extension.
Over 70% of participants on 120 mg lost at least 10% of body weight, and nearly 40% lost at least 15%.
Clinically meaningful improvements in systolic blood pressure (-6.4 to -7.5 mmHg) and HbA1c (-0.28% to -0.37%) were observed, even in participants without diabetes.
Safety and tolerability
GI-related adverse events (nausea, vomiting) were most common, peaking early and mostly mild to moderate, with overall AE-related discontinuation rates of 7.7% to 13.3% (mean 10.4%) in Phase 2b.
No AE-related discontinuations occurred at higher doses (180/240 mg) after titration in ACCESS II and in studies using a 2.5 mg starting dose.
No cases of drug-induced liver injury, persistent liver enzyme elevations, or QTc prolongation were observed in over 500 patients.
Quantify 2.5mg start's impact on discontinuations
Aleniglipron's competitive edge vs. oral GLP-1s?
Rationale for 240mg dose in Phase 3 design?
How does 240mg data inform Phase III dosing?
How does 2.5mg start improve aleniglipron tolerability?
What is the strategic role of amylin assets?
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Next Structure Therapeutics earnings date
Q4 202527 Feb, 2026
Next Structure Therapeutics earnings date
Q4 202527 Feb, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
Related articles
)
)
Frequently asked questions
Structure Therapeutics Inc., known by its Nasdaq ticker symbol GPCR, is a clinical-stage global biopharmaceutical company that focuses on designing innovative, orally available small molecule medicines. The company aims to transform the lives of patients worldwide by leveraging advanced computing and structure-based technologies. Its mission is to replace biologics and peptides with small-molecule drugs that offer life-changing solutions. The company is headquartered in San Francisco, California, and its shares are listed on the Nasdaq.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage